Bayer has filed with the European Medicines Agency for authorization to market Recothrom as a topical aid to control surgical bleeding.
Recothrom received FDA approval in January 2008. Recothrom is being commercialized in a global collaboration between ZymoGenetics and Bayer which began in June 2007.
Bruce Carter, CEO of ZymoGenetics, said: “Bayer’s filing for approval in Europe demonstrates their commitment to Recothrom. Bayer has been a valued partner in selling Recothrom, the first and only plasma-free thrombin, in the US and in driving the ex-US program forward.”